Can Fite Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.06.24	Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix (Businesswire)
24.06.24	Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver (Businesswire)
10.06.24	Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study (Businesswire)
05.06.24	Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study (Businesswire)
29.05.24	Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases (Businesswire)
27.05.24	Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 (Businesswire)
23.05.24	Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6 (Businesswire)
13.05.24	Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study (Businesswire)
09.05.24	Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study (Businesswire)
06.05.24	Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 (Businesswire)
25.04.24	Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal (Businesswire)
15.04.24	Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH (Businesswire)
03.04.24	Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients (Businesswire)
11.03.24	Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference (Businesswire)
28.02.24	Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada (Businesswire)
30.01.24	Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication (Businesswire)
29.01.24	Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study (Businesswire)
20.12.23	The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies (Businesswire)
18.12.23	Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan (Businesswire)
04.12.23	Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development (Businesswire)
30.11.23	Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update (Businesswire)
21.11.23	Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson (Businesswire)
01.11.23	Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track (Businesswire)
30.10.23	Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action (Businesswire)
26.10.23	Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs (Businesswire)
09.10.23	Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies (Businesswire)
27.09.23	Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) (Businesswire)
07.09.23	Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference (Businesswire)
31.08.23	Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies (Businesswire)
24.08.23	Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome (Businesswire)
18.08.23	Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis (Businesswire)
17.07.23	Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation (Businesswire)
07.07.23	Can-Fite to Present at the Emerging Growth Conference on July 13, 2023 (Businesswire)
29.06.23	Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan (Businesswire)
13.06.23	Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson (Businesswire)
02.06.23	Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston (Businesswire)
01.06.23	Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update (Businesswire)
30.05.23	Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO) (Businesswire)
15.05.23	Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023 (Businesswire)
09.05.23	Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients (Businesswire)
02.05.23	Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists (Businesswire)
24.04.23	Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization (Businesswire)
10.04.23	Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment (Businesswire)
30.03.23	Can-Fite Reports 2022 Financial Results & Provides Clinical Update (Businesswire)
16.03.23	Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson (Businesswire)
13.03.23	Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting (Businesswire)
14.02.23	Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo (Businesswire)
24.01.23	Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed (Businesswire)
11.01.23	Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement (Businesswire)
10.01.23	Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	160.55	6.32 %	K V
Logitech Intl	86.44	3.10 %	K V
Lonza Grp	536.80	2.56 %	K V
Sika	175.60	1.92 %	K V
Givaudan	3’442.00	1.83 %	K V
Zurich Insur Gr	576.40	-0.21 %	K V
Roche Hldg G	284.10	-0.73 %	K V
Geberit	598.00	-1.09 %	K V
Holcim	66.94	-1.09 %	K V
UBS Group	31.34	-1.45 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Can Fite Biopharma Aktie VALOR 19483041 / ISIN US13471N1028

Nachrichten zu Can Fite Biopharma Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten